FindTrial
Sign In

CHOLESTEROL MANAGEMENT IN CORONARY ARTERY DISEASE: ATORVASTATIN VERSUS ROSUVASTATIN-WHICH TO CHOOSE?

GUIDELINE TARGETED DYSLIPIDEMIA MANAGEMENT IN THE REAL WORLD SCENARIO-EFFECTIVENESS OF ATORVASTATIN VERSES ROSUVASTATIN IN PATIENTS WITH CORONARY ARTERY DISEASE-AN OBSERVATIONAL STUDY

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/04/051592
Enrollment
500
Registered
2023-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I259- Chronic ischemic heart disease, unspecified

Interventions

None listed

Sponsors

Prof Rajan Joseph Manjuran
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: CORONARY ARTERY DISEASE PATIENTS ON STATIN THERAPY EITHER WITH ATORVASTATIN OR ROSUVASTATIN, FOR AT LEAST 3 MONTHS

Exclusion criteria

Exclusion criteria: PATIENTS WHO ARE NOT WILLING TO GIVE CONSENT

Design outcomes

Primary

MeasureTime frame
PROPORTION OF PATIENTS ATTAIN RECOMMENDED LDL VALUE ON ATORVASTATIN VERSES THOSE ON ROSUVASTATIN. MEAN HIGH DENSITY LIPOPROTEIN(HDL) LEVELS IN EACH OF THE TREATMENT GROUPS.Timepoint: 3 MONTHS—

Secondary

MeasureTime frame
MOST FREQUENTLY USED DOSE OF ATORVASTATIN AND ROSUVASTATIN IN REGULAR CLINICAL PRACTICE. PERCENTAGE OF PATIENTS ON HIGH INTENSITY STATIN MEDICATION. COMPARE THE PROPORTION OF PATIENTS DEVELOPING SIDE EFFECTS IN EACH OF THE GROUP.Timepoint: 3 MONTHS—

Countries

India

Contacts

Public ContactProf Dr Rajan Joseph Manjuran

Pushpagiri Institute of Medical Science and Research Centre

rjmanjuran@pushpagiri.in9188607054

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026